GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Asset Turnover

Bruker (Bruker) Asset Turnover

: 0.21 (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bruker's Revenue for the three months ended in Dec. 2023 was $855 Mil. Bruker's Total Assets for the quarter that ended in Dec. 2023 was $4,035 Mil. Therefore, Bruker's Asset Turnover for the quarter that ended in Dec. 2023 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. Bruker's annualized ROE % for the quarter that ended in Dec. 2023 was 63.57%. It is also linked to ROA % through Du Pont Formula. Bruker's annualized ROA % for the quarter that ended in Dec. 2023 was 20.37%.


Bruker Asset Turnover Historical Data

The historical data trend for Bruker's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.68 0.72 0.70 0.75

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.19 0.18 0.19 0.21

Competitive Comparison

For the Medical Devices subindustry, Bruker's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker Asset Turnover Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bruker's Asset Turnover falls into.



Bruker Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bruker's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2964.5/( (3611.8+4249.9)/ 2 )
=2964.5/3930.85
=0.75

Bruker's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=854.5/( (3819.6+4249.9)/ 2 )
=854.5/4034.75
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bruker  (NAS:BRKR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bruker's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=822/1293
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(822 / 3418)*(3418 / 4034.75)*(4034.75/ 1293)
=Net Margin %*Asset Turnover*Equity Multiplier
=24.05 %*0.8471*3.1205
=ROA %*Equity Multiplier
=20.37 %*3.1205
=63.57 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bruker's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=822/4034.75
=(Net Income / Revenue)*(Revenue / Total Assets)
=(822 / 3418)*(3418 / 4034.75)
=Net Margin %*Asset Turnover
=24.05 %*0.8471
=20.37 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bruker Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bruker's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139